Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:CRMD NASDAQ:JBIO NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$4.53-1.4%$3.57$1.03▼$5.34$972.02M1.553.81 million shs3.09 million shsCRMDCorMedix$14.17-3.2%$12.27$5.31▼$17.43$1.06B1.762.12 million shs2.34 million shsJBIOJade Biosciences$7.70+1.0%$8.52$6.57▼$105.00$251.25M1.04161,143 shs18,268 shsSYRESpyre Therapeutics$16.76+0.8%$16.35$10.91▼$40.26$1.01B2.87601,971 shs105,479 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences+0.22%-4.97%+10.07%+85.83%+253.08%CRMDCorMedix-1.28%+4.65%+25.77%+18.26%+134.62%JBIOJade Biosciences-3.54%-5.11%+10.60%+761,999,900.00%+761,999,900.00%SYRESpyre Therapeutics+0.85%-2.52%+2.28%+0.67%-42.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIatai Life Sciences3.5046 of 5 stars4.63.00.00.02.11.70.6CRMDCorMedix2.636 of 5 stars3.41.00.00.03.40.01.9JBIOJade Biosciences2.2384 of 5 stars3.50.00.00.03.21.70.0SYRESpyre Therapeutics2.4614 of 5 stars3.60.00.00.04.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIatai Life Sciences 3.17Buy$11.25148.62% UpsideCRMDCorMedix 2.86Moderate Buy$17.3322.37% UpsideJBIOJade Biosciences 3.00Buy$16.00107.79% UpsideSYRESpyre Therapeutics 3.29Buy$53.40218.71% UpsideCurrent Analyst Ratings BreakdownLatest JBIO, CRMD, ATAI, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ATAIatai Life SciencesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/14/2025JBIOJade BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.008/8/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $17.008/6/2025SYRESpyre TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$65.007/30/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $15.007/29/2025ATAIatai Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$14.007/28/2025ATAIatai Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.007/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/2/2025ATAIatai Life SciencesAegisSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/2/2025ATAIatai Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.006/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIatai Life Sciences$2.31M420.04N/AN/A$0.67 per share6.75CRMDCorMedix$43.47M24.33N/AN/A$2.96 per share4.79JBIOJade BiosciencesN/AN/AN/AN/A$6.18 per shareN/ASYRESpyre Therapeutics$890K1,137.08N/AN/A$4.97 per share3.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIatai Life Sciences-$149.27M-$0.69N/AN/AN/AN/A-85.43%-64.38%11/12/2025 (Estimated)CRMDCorMedix-$17.93M$0.7518.8915.07N/A42.11%42.73%34.19%10/29/2025 (Estimated)JBIOJade Biosciences-$69.63M-$30.33N/A∞N/AN/A-51.96%-47.65%N/ASYRESpyre Therapeutics-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)Latest JBIO, CRMD, ATAI, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ATAIatai Life Sciences-$0.12-$0.14-$0.02-$0.14N/A$0.72 million8/13/2025Q2 2025JBIOJade Biosciences-$0.43-$0.86-$0.43-$0.86N/AN/A8/7/2025Q2 2025CRMDCorMedix$0.20$0.28+$0.08$0.28$29.88 million$39.74 million8/5/2025Q2 2025SYRESpyre Therapeutics-$0.73-$0.49+$0.24-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIatai Life SciencesN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIatai Life Sciences0.024.024.02CRMDCorMedixN/A7.827.52JBIOJade BiosciencesN/A10.3110.31SYRESpyre TherapeuticsN/A6.496.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIatai Life Sciences28.41%CRMDCorMedix34.18%JBIOJade BiosciencesN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipATAIatai Life Sciences26.80%CRMDCorMedix5.30%JBIOJade Biosciences24.90%SYRESpyre Therapeutics6.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIatai Life Sciences80214.34 million156.90 millionOptionableCRMDCorMedix3074.65 million70.69 millionOptionableJBIOJade Biosciences2032.63 million24.50 millionN/ASYRESpyre Therapeutics7360.40 million56.66 millionOptionableJBIO, CRMD, ATAI, and SYRE HeadlinesRecent News About These CompaniesParadigm Biocapital Advisors LP Buys 600,000 Shares of Spyre Therapeutics, Inc. $SYRESeptember 2 at 7:09 AM | marketbeat.comNuveen LLC Makes New Investment in Spyre Therapeutics, Inc. $SYRESeptember 1 at 3:33 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Lowered to Sell Rating by Wall Street ZenSeptember 1 at 2:37 AM | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street ZenSeptember 1 at 2:10 AM | marketbeat.comDriehaus Capital Management LLC Sells 86,343 Shares of Spyre Therapeutics, Inc. $SYREAugust 31 at 7:14 AM | marketbeat.comAffinity Asset Advisors LLC Decreases Holdings in Spyre Therapeutics, Inc. $SYREAugust 28, 2025 | marketbeat.comVanguard Group Inc. Buys 51,794 Shares of Spyre Therapeutics, Inc. $SYREAugust 28, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to "Hold" RatingAugust 25, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5% - Here's WhyAugust 15, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 12, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 9, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from WedbushAugust 7, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPSAugust 6, 2025 | marketbeat.comSpyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 5, 2025 | globenewswire.comTD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)August 5, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsAugust 1, 2025 | globenewswire.comHere's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn SituationJuly 16, 2025 | finance.yahoo.comSYRE - Spyre Therapeutics Inc Trailing Returns - MorningstarJuly 4, 2025 | morningstar.comMSpyre Therapeutics Announces Grants of Inducement AwardsJuly 3, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)June 20, 2025 | theglobeandmail.comSpyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardJune 18, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJBIO, CRMD, ATAI, and SYRE Company Descriptionsatai Life Sciences NASDAQ:ATAI$4.53 -0.07 (-1.42%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.CorMedix NASDAQ:CRMD$14.16 -0.48 (-3.24%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Jade Biosciences NASDAQ:JBIO$7.70 +0.08 (+1.05%) As of 02:28 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$16.76 +0.13 (+0.75%) As of 02:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
